ZYMOGENETICS PRESENTS PHASE II THROMBIN RESULTS

ZymoGenetics has presented the aggregate results of four Phase II clinical studies of recombinant human Thrombin (rhThrombin) at the International Society on Thrombosis and Hemostasis annual meeting in Sydney, Australia.

The combined Phase II study results showed that rhThrombin, a product candidate in development to control bleeding during surgery, appeared to be safe and well-tolerated, with a favorable immunogenicity profile. A total of 130 patients undergoing spinal surgery, liver resection, peripheral artery bypass, or arteriovenous graft construction were evaluated.